GlaxoSmithKline Consumer Healthcare GmbH, Germany
| Държава: | ----- |
| Кратка информация: | Transforming R&D to ensure we not only deliver the current pipeline but are also able to sustain the flow of products for years to come. With the aim of sustaining an industry-leading pipeline of products that deliver value for healthcare providers, we have been focusing on improving rates of return and delivering the best science in our R&D organisation. This has required a multi-faceted approach. For example we have increased the level of externalisation of our research, taken difficult decisions around pipeline progressions and focused on disease areas where we believe the prospects for successful registration and launch of differentiated medicines are greater. We have one of the largest development pipelines in the industry with approximately 30 late-stage assets. The vast majority of these programmes address unmet medical need and importantly nearly two-thirds are new chemical entities or new vaccines. Our plansAndrew Witty Focus on the best science Diversify through externalisation Re-personalise R&D Focus on return on investment |
| Сайт: | http://www.gsk.com |
Търсене в сайта
Лекарствен справочник
http://sommons.co/out?zoneId=2647810-2647961 Банер II
